| 肠道菌群在炎症性肠病发病机制与治疗中的作用研究进展 |
| |
| 引用本文： | 彭衡英, 刘吉华. 肠道菌群在炎症性肠病发病机制与治疗中的作用研究进展[J]. 药学进展, 2021, 45(8): 627-636. |
| |
| 作者姓名： | 彭衡英 刘吉华 |
| |
| 作者单位： | 1.中国药科大学江苏省中药评价与转化重点实验室, 江苏 南京 211198 |
| |
| 摘 要： | 炎症性肠病是一种以肠道炎症和黏膜损伤为特征的慢性疾病，主要包括克罗恩病和溃疡性结肠炎，其发病原因尚不明确。现有研究表明炎症性肠病的发病机制与宿主的遗传易感性、肠道菌群紊乱、肠黏膜屏障破坏和肠黏膜免疫异常等密切相关。总结目前炎症性肠病发病机制、患者肠道菌群结构及治疗方法等相关的研究进展，旨在对今后炎症性肠病的治疗和药物研发有所裨益。
|
| 关 键 词： | 炎症性肠病 肠道菌群 肠道屏障 发病机制 治疗方法 |
| 收稿时间： | 2020-06-20 |
Advances in Research on Intestinal Flora in the Pathogenesis and Treatment of Inflammatory Bowel Disease |
| |
| PENG Hengying, LIU Jihua. Advances in Research on Intestinal Flora in the Pathogenesis and Treatment of Inflammatory Bowel Disease[J]. Progress in Pharmaceutical Sciences, 2021, 45(8): 627-636. |
| |
| Authors: | PENG Hengying LIU Jihua |
| |
| Affiliation: | 1.Jiangsu Key Laboratory of TCM Evaluation and Translational Research, China Pharmaceutical University, Nanjing 211198, China |
| |
| Abstract: | Inflammatory bowel disease(IBD) is a chronic disease characterized by intestinal inflammation and mucosal damage, including mainly Crohn,s disease(CD) and ulcerative colitis(UC), still with unknown etiopathogenesis. Current studies have found that its pathogenesis is closely related to the host,s genetic susceptibility, intestinal flora dysbiosis, intestinal mucosal barrier damage and intestinal mucosal immune abnormalities. In this review, the related research progress of the mechanism of IBD, the structure of patients, intestinal flora and treatment methods are summarized, in an attempt to provide some reference for the development of new therapies and new drugs against inflammatory bowel disease in the future. |
| |
| Keywords: | inflammatory bowel disease intestinal flora intestinal barrier pathogenesis therapy |
|
| 点击此处可从《药学进展》浏览原始摘要信息 |
|
点击此处可从《药学进展》下载全文 |
